28th Apr 2014 11:51
LONDON (Alliance News) - Silence Therapeutics PLC said Monday that it had successfully translated data from trials with rodents of its Ribonucleic acid lung delivery system DACC to non-human primates, showing it can deliver Ribonucleic acid to multiple tissues.
Ribonucleic acid is a family of larger molecules that can be used to code, decode, regulate and express genes. It has a similar structure to DNA. It can be delivered into the cell to reduce the level at which genetic code is interpreted by the body, in a technique known as genetic knockdown.
Silence said that its systemic vasculature delivery system, AtuPlex, is being used in human clinical trials with "an excellent safety profile."
The company said that its ability to deliver Robonucleic acid payloads to multiple tissues using the DACC system gives it "a wide variety of choice from which to build a drug pipeline."
Shares in Silence Therapeutics were trading up 0.6% at 256.51 pence Monday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L